DISRUPT: a randomised phase 2 trial of ombrabulin (AVE8062) plus a taxane-platinum regimen as first-line therapy for metastatic non-small cell lung cancer.
about
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer.Synthesis and anti-cancer screening of novel heterocyclic-(2H)-1,2,3-triazoles as potential anti-cancer agents.Early investigational tubulin inhibitors as novel cancer therapeutics.Microtubule destabilising agents: far more than just antimitotic anticancer drugs.Newly developed anti-angiogenic therapy in non-small cell lung cancer.Starvation tactics using natural compounds for advanced cancers: pharmacodynamics, clinical efficacy, and predictive biomarkers.
P2860
DISRUPT: a randomised phase 2 trial of ombrabulin (AVE8062) plus a taxane-platinum regimen as first-line therapy for metastatic non-small cell lung cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
DISRUPT: a randomised phase 2 ...... ic non-small cell lung cancer.
@en
DISRUPT: a randomised phase 2 trial of ombrabulin
@nl
type
label
DISRUPT: a randomised phase 2 ...... ic non-small cell lung cancer.
@en
DISRUPT: a randomised phase 2 trial of ombrabulin
@nl
prefLabel
DISRUPT: a randomised phase 2 ...... ic non-small cell lung cancer.
@en
DISRUPT: a randomised phase 2 trial of ombrabulin
@nl
P2093
P50
P1433
P1476
DISRUPT: a randomised phase 2 ...... tic non-small cell lung cancer
@en
P2093
Augustin Rey
Aurore Allard
DISRUPT Investigators
Jaafar Bennouna
Joachim von Pawel
Martin Reck
Mustapha Chadjaa
Vera Gorbounova
P304
P356
10.1016/J.LUNGCAN.2014.05.013
P577
2014-05-21T00:00:00Z